Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chuikyo Recommends
May 8, 2006
- Gabapentin, Mozavaptan
May 8, 2006
- JPMA Asks Korosho to Lighten Industry's
May 8, 2006
- MEDICAL DEVICE NEWS IN BRIEF
May 8, 2006
- STATISTICS
May 8, 2006
- SEMINAR
May 8, 2006
- REGULATORY NEWS IN BRIEF
May 8, 2006
- RDKK Supports Nursery for Female Doctors with Children
May 8, 2006
- JT Licenses New Drug Candidate to GSK
May 8, 2006
- SELF-MEDICATION NEWS IN BRIEF
May 8, 2006
- DIA WORKSHOP
May 8, 2006
- SURVEY 2 articles
May 8, 2006
- R&D NEWS IN BRIEF
May 8, 2006
- Sanofi-aventis Aims to
May 8, 2006
- Dr A. Endo Awarded Japan Prize for Discovery of Statins
May 8, 2006
- Hib Vaccine to Be Approved in 2006: Sanofi Pasteur
May 8, 2006
- SEMINAR
May 8, 2006
- Bayer Takeover of Schering
May 8, 2006
- OPINION
May 8, 2006
- GCP Auditing Business
May 8, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…